Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

COVID To GLP-1: Catalent Plants Ride With Novo To Next Public Health Crisis

Feb 26 2024

• By Bowman Cox

Wegovy pen — Time for the next big thing • Source: Shutterstock

Related Content

Ranbaxy’s $500 Million Settlement Includes Criminal Penalties

May 14 2013

Wegovy Manufacturing Delays Highlight Challenges Of Managing Aging Facility Risks

Feb 16 2022

FDA Allowed Release Of Moderna COVID Booster While Still Mulling Plant Inspection Findings

Sep 27 2022

How Post-Approval GMP Challenges Cooled Novo Nordisk’s Blazing Wegovy Launch

Jan 05 2022

The Quality Lowdown: More Inspection Delays, More Findings On Sterility And Investigations

Jan 23 2022

Why Data Integrity Concerns Led Fresenius To Back Away From Akorn Deal

May 14 2018

Novo Splashes Out Again To Solve Semaglutide Supply Problem

Feb 05 2024

Able Labs Recall Of All Marketed Products Boosts 2005 Drug Recall Total

Feb 27 2006

Related Companies

Catalent, Inc

Novo Nordisk A/S

Bristol Myers Squibb Company

Moderna, Inc.

Johnson & Johnson

Daiichi Sankyo Co., Ltd.

Eli Lilly and Company

Siegfried AG

Additional Topics

Manufacturing Supply Chain M & A Coronavirus COVID-19 Advertising, Marketing & Sales Quality Market Access Compliance BioPharmaceutical

More from Manufacturing Focus

More from In Vivo

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window